RPRX
Royalty Pharma plc
NASDAQ · USHealthcareBiotechnology
$57.30-1.52%
Price as of Jul 20, 2026
RPRX financials
Royalty Pharma plc financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $2.4B | $2.3B | $2.4B | $2.2B |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $2.4B | $2.3B | $2.4B | $2.2B |
| Operating expenses | $818.7M | $971.1M | $862.4M | $1.9B |
| Operating income | $1.6B | $1.3B | $1.5B | $307.1M |
| Net income | $770.9M | $859.0M | $1.1B | $42.8M |
| EBITDA | $1.6B | $1.6B | $1.9B | $423.7M |
| Basic EPS | $2.33 | $1.92 | $3.41 | $0.10 |
| Diluted EPS | $1.80 | $1.91 | $2.53 | $0.10 |
| Balance sheet | ||||
| Cash & equivalents | $618.7M | $929.0M | $477.0M | $1.7B |
| Total assets | $19.6B | $18.2B | $16.4B | $16.8B |
| Total liabilities | $9.9B | $7.9B | $6.3B | $7.3B |
| Stockholders’ equity | $6.5B | $6.9B | $6.5B | $5.6B |
| Total debt | $9.0B | $7.6B | $6.1B | $7.1B |
| Net debt | $8.3B | $6.7B | $5.7B | $5.4B |
| Cash flow | ||||
| Operating cash flow | $2.5B | $2.8B | $3.0B | $2.1B |
| Capital expenditure | $0.00 | $0.00 | $0.00 | $0.00 |
| Free cash flow | $2.5B | $2.8B | $3.0B | $2.1B |
| Dividends paid | -$378.3M | -$376.5M | -$358.3M | -$333.3M |
| Share repurchases | -$1.2B | -$229.7M | -$304.8M | $0.00 |